% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • johnpapas893 johnpapas893 Jun 6, 2013 9:31 PM Flag

    European Hematology Association (EHA)

    Bear, Kot, and Vin
    Are we likely to see any new data (beyond those presented at ASCO) next week in the EHA meetings?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • The most of the data for ASCO was submitted Mid-February...However, I think that some was also quite fresh...I doubt that in such a short period of time they've prepared any new results. I also don't think that this meeting will affect s/p,- we've started leg up and, probably, in some choppy way in 4-7 weeks will make new high...

      • 1 Reply to kot882001
      • I think that the case for Kyrpolis was largely made in the Kyota conference on multiple myeloma. The CRD (carfilzomib/revlimid/dexamethasone) combo therapy will gradually become the accepted first line treatment for MM around the world. It's always a revelation to me that the new therapies in these conditions are adopted first in the academic settings and larger medical centers and take a while to filter down to your friendly neighborhood oncologist.(There are newly diagnosed MM patients right now who are being put on Velcade, which is demonstrably inferior to Kyrpolis.) The next major news for Kyrpolis should be when the quarterly earnings are reported early in August, when we see just how widely adopted this drug has been. In terms of hematology, the next big news from Onyx should be the trials of oprozomib, which are just recruiting now.